Navigation Links
Major advanced cancer study to be led by Uppsala University
Date:8/18/2011

Several prominent cancer researchers are now joining forces in an advanced new cancer study. The goal is to understand which tumors will be difficult to treat and to find out why certain cancer drugs lose their effect after a period of use. The study is to be directed by Tobias Sjblom, associate professor of tumor biology at Uppsala University, Sweden.

The study involves a hundred cancer patients, suffering from either cancer of the large intestine or chronic lymphatic leukemia. Samples will be taken from patients both before and after drug treatment. The aim is to find out what makes so many tumors resistant to treatment a major problem in cancer care today.

"With this initiative we will have a unique opportunity to study the development of tumors up close. Several research teams will examine the samples using different analytical methods in order to get an overall picture," says Tobias Sjblom, associate professor of tumor biology at Uppsala University and director of the study.

What lies behind this resistance is not known today, but it is assumed to emerge when the tumor changes over time, mutates. This also alters the original approach to treatment. In the study scientists will be looking for mutations in all the genes in the tumors.

The study is to be performed by Uppsala scientists together with colleagues from the Royal Institute of Technology, the Swedish University of Agricultural Sciences, and Ume University. It is made possible by funding from SciLifeLab, a total of SEK 4.5 million over two years. All analyses will be done at SciLifeLab, which is a national resource center for medical and bioscience research.

"This is a model for how we want to work with large projects within SciLifeLab. Researchers receiving funding from us have access to our resources in the form of technologically advanced equipment and competence, while their own expertise in the specific research field ensures that the right questions are being asked. This enables us to generate new knowledge about diseases more quickly," says Kerstin Lindblad-Toh, director of SciLifeLab Uppsala.

This type of research is also of interest to the pharmaceuticals industry.

"The industry will have an opportunity to assess the effect of their drugs, and we hope this will provide greater insights into how we can predict how different patients will react to a certain medicine in the future," says Tobias Sjblom.


'/>"/>

Contact: Tobias Sjblom
tobias.sjoblom@igp.uu.se
46-070-167-9039
Uppsala University
Source:Eurekalert

Related medicine news :

1. Seattle Childrens lands major funding with hopes of saving thousands of infant lives
2. Group Health establishes major initiative to prevent opioid abuse and overdose
3. Nottingham scientist wins major cancer research award
4. Major award for leading expert in regenerative medicine
5. Obesity a Major Cause of Early Death in Women: Study
6. Major malaria drug research award
7. Lawmakers Urged to Consider Health Effects of Major Legislation
8. Government should consider public health implications of all major legislation
9. Deaths and major morbidity from asbestos-related diseases in Asia likely to surge in next 20 years
10. UB played major role in study on drug that reduces breast cancer in high-risk women
11. New advances in lipid genetics lead to better detection and prevention of major diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... "The World Market for Companion Diagnostic Tests" report to ... World Market for Companion Diagnostics The World ... diagnostic and personalized medicine diagnostics. Market analysis in the report ... Diagnostics Test Market (In Vitro Diagnostic Kits) by Region (N. ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
Breaking Medicine Technology: